gilead sciences

Science
Health & Safety

Remdesivir Priced At More Than $3,100 For A Course Of Treatment

7:39pm June 29, 2020

by Sydney Lupkin

An experimental COVID-19 medicine that has been shown to shorten the time people with severe illness have to stay in the hospital finally has a price tag that's lower than some analysts expected.

Queue Listen Now

Gilead Sciences CEO Daniel O'Day speaks at a meeting with President Trump and members of the White House coronavirus task force on March 2.

Politics & Government
Health & Safety

Gilead Lobbying Rose As Interest In COVID-19 Treatment Climbed

11:51am May 02, 2020

by Sydney Lupkin

On Friday, the Food and Drug Administration authorized emergency use of remdesivir for patients with severe cases of COVID-19. Drugmaker Gilead Sciences' lobbying hit a new high in the first quarter.

After the Food and Drug Administration granted Gilead Sciences orphan drug status for its experimental drug remdesivir on Tuesday, Gilead asked that the agency rescind that status Wednesday.

Science
Health & Safety

Gilead Declines 'Rare Disease' Status For Experimental Coronavirus Drug

7:30pm March 25, 2020

by Sydney Lupkin

By renouncing the special status, Gilead Sciences lets go of tax breaks, fee waivers and seven years without generic competition for remdesivir, its experimental COVID-19 treatment.